Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: Results from a modelling exercise

Journal of Medical Economics

Volumn 13, Issue 2, 2010, Pages 284-294

  Torvinen, Saku ^a   Nieminen, Pekka ^b   Lehtinen, Matti ^c   Paavonen, Jorma ^b   Demarteau, Nadia ^d   Hahl, Jarmo ^e  

^a GLAXOSMITHKLINE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e Abbott   (Finland)

Author keywords

Cervical cancer; Cost effectiveness; Human papillomavirus; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CALIBRATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FINLAND; HEALTH CARE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFANT; MAJOR CLINICAL STUDY; MARKOV COHORT MODEL; MATHEMATICAL MODEL; MORTALITY; OUTCOMES RESEARCH; PAPANICOLAOU TEST; PREDICTION; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; UTERINE CERVIX CANCER;

ADULT; CHILD; COST-BENEFIT ANALYSIS; FEMALE; FINLAND; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77953341690     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.485951     Document Type: Article

References (70)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Adams M, Jasani B, Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007;25:3007-3013.
3. Anttila A, Pukkala E, Soderman B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65.
4. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(Suppl 1):S16-24.
5. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24(Suppl 1):S1-15.
6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
7. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-632.
8. Suarez E, Smith J, Bosch F, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 2008;26S:F29-45.
9. Beby-Defaux A, Bourgoin A, Ragot S, et al. Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 2004;73:262-268.
10. Boulanger JC, Sevestre H, Bauville E, et al. [Epidemiology of HPV infection]. Gynecol Obstet Fertil 2004;32:218-223.
11. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-1623.
12. Dalstein V, Riethmuller D, Sautiere JL, et al. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 2004;40:1225-1232.
13. Riethmuller D, Gay C, Bertrand X, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 1999;8:157-164.
14. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
15. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-258.
16. Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-735.
17. Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95:1336-1343. (Pubitemid 37160867)
18. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-1423.
19. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
20. Molano M, Van den BA, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486-494.
21. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358:1782-1783.
22. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-3114.
23. lääkäriseura Duodecimin ja Suomen kolposkopiayhdistyksen asettama työryhmä. Suomalaisen. Käypä hoito -suositus: Kohdunkaulan, emättimen ja ulkosynnytinten solumuutokset - diagnostiikka, hoito ja seuranta. Duodecim 2006;122:1808-1833.
24. Finnish Cancer Registry. http://www.cancerregistry.fi. 2007.
25. Monto K, Nieminen P. Gynekologisten irtosolunäytteiden määrät ja raportointitavat Suomessa. Suom Lääkäril 2005;18-19/ 2005:2093-2097.
26. Nieminen P, Kallio M, Anttila A, et al. Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999;83:55-58.
27. Paavonen J, Jenkins D, Bosch F, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170.
28. Paavonen J. Mitä HPV-rokotteilta voidaan odottaa? Suomen Lääkärilehti 2009;11:1017-1021.
29. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-689.
30. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-819.
31. Nieminen P, Vuorma S, Viikki M, et al. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. BJOG 2004;111:842-848.
32. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):S3-26/34.
33. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-998.
34. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-11565
35. FIGO. (International Federation of Gynecology and Obstetrics) 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S1-257.
36. Statistics Finland. www.stat.fi. 2008.
37. Hujanen T, Kapiainen S, Tuominen U, et al. Terveydenhuollon yksikko ̈kustannukset Suomessa vuonna 2006 (Healthcare unit costs in Finland 2006). 3/2008, 1-107. 2008. Helsinki, Stakes. Työpapereita.
38. Helsingin ja Uudenmaan airaanhoitopiiri. Hinnasto 2008. (Official price list of Hospital District of Heslinki and Uusimaa). 2008.
39. Varsinais-Suomen sairaanhoitopiiri. Palveluhinnasto 2008. (Official price list of Hospital District of Southwest Finland, 2008). http:/// www.vsshp.fi. 2008.
40. SLD Price [Finnish Pharmaceutical Data Ltd/Suomen Lääkedata Oy; 2008.
41. Health Outcomes Data Repository. https://crc-limited.co.uk. 2007. Cardiff Research Consortium.
42. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-1122.
43. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation. (Abstract n- 542 presented at the Twenty-First International Papillomavirus Conference, México City, México. February 20-27). 2004.
44. Rokotuskattavuus Suomessa. (Vaccination coverage in Finland). http://www.ktl.fi/portal/suomi/terveyden-ammattilaisille/rokottaminen/ rokotuskattavuus/. 2010. Terveyden ja Hyvinvoinnin Laitos (National Institute for Health and Welfare). 23-2-2010.
45. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-1255.
46. Sosiaali- ja terveysministeriön asetus lääkkeiden hintalautakunnalle tehtävästä hakemuksesta ja hintailmoituksesta. (Guideline for Health Economic Evaluation). 27 Mar. 2009. Sosiaali- ja terveysministerio ̈ (Ministry of Social Affairs and Health). 201/2009. http:// www.finlex.fi/fi/laki/alkup/2009/20090201 Accessed 23 Feb. 2010.
47. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500.
48. @RISK for Excel. Version 4.5.5 (US/English) [Palisade Corporation; 2005.
49. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-517.
50. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
51. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006;28:88-100.
52. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003;23:76-82.
53. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993;15:265-302.
54. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005;191(Suppl 1):S97-106.
55. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999;18:3263-3282.
56. Harper D, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with CervarixTM (GSK's HPV 16/18 AS04 candidate vaccine). Late-breaking abstracts presented for the 39th Annual Meeting of the Society of Gynecologic Oncologists, 9-12 March, Tampa, USA). Gynecol Oncol 2008;109:158.
57. Barr E, Gause CK, Bautista OM, et al. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol 2008;198:261.e1-11
58. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003;106:896-904.
59. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-1923.
60. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007;96:143-150.
61. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006;3:e138.
62. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-615.
63. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002;13:631-639.
64. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-789.
65. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9:37-48.
66. Van De Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007;165:762-775.
67. Lasten rotavirusrokotustyöryhmä. Kansanterveyslaitoksen asettama lasten rotavirusrokotustyöryhmän selvitys. B28/2007. 26-11-2007. Helsinki, Kansanterveyslaitos (National Public Health Institute, Finland). Kansanterveyslaitoksen julkaisuja.
68. Lasten pneumokokkirokotustyöryhmä. Kansanterveyslaitoksen asettama lasten pneumokokkirokotustyöryhmän selvitys. B12/2008. 2008. Helsinki, Kansanterveyslaitos (National Public Health Institute, Finland). Kansanterveyslaitoksen julkaisuja.
69. Bell S, Porter M, Kitchener H, et al. Psychological response to cervical screening. Prev Med 1995;24:610-616.
70. Lerman C, Miller SM, Scarborough R, et al. Adverse psychologic consequences of positive cytologic cervical screening. Am J Obstet Gynecol 1991;165:658-662.